Vor Biopharma Inc. (NYSE:VOR) Receives $11.36 Average Price Target from Analysts

Shares of Vor Biopharma Inc. (NYSE:VOR) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $11.36.

Several brokerages have weighed in on VOR. JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a report on Tuesday, December 10th. Robert W. Baird cut their price target on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Vor Biopharma in a report on Monday, December 9th. Finally, HC Wainwright restated a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th.

Vor Biopharma Stock Performance

NYSE VOR opened at $0.89 on Tuesday. Vor Biopharma has a 52-week low of $0.63 and a 52-week high of $3.14. The firm’s 50 day moving average price is $0.83 and its 200-day moving average price is $0.91. The company has a market cap of $60.89 million, a PE ratio of -0.54 and a beta of -0.37.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.40). On average, analysts forecast that Vor Biopharma will post -1.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VOR. Renaissance Technologies LLC raised its position in shares of Vor Biopharma by 48.0% in the second quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after buying an additional 160,642 shares during the last quarter. Rosalind Advisors Inc. purchased a new stake in Vor Biopharma during the 3rd quarter valued at about $54,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vor Biopharma in the 2nd quarter valued at about $63,000. Cubist Systematic Strategies LLC purchased a new position in Vor Biopharma in the 2nd quarter worth approximately $53,000. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Vor Biopharma by 40.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock worth $116,000 after purchasing an additional 48,017 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.